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The aim of this study was to compare the clinical ecacy and acceptability of salbutamol inhaled via Easyhaler1
and Turbuhaler1 multi-dose dry powder inhalers in the treatment of histamine-induced bronchoconstriction.
Thirty-two adult patients with asthma and/or bronchial hyper-reactivity were included in the study, which was
carried out according to a randomized, double-blind, double-dummy, cross-over design. Histamine challenge test
was performed on 2 study days separated by at least 7 days. The challenge test was continued until a 20% fall in
forced expiratory volume in 1 sec (FEV1) was achieved. The patients then inhaled a single 100 mg dose of salbutamol
from Easyhaler1, or from Turbuhaler1. FEV1 was assessed by flow–volume spirometry before and after histamine
challenge and 1?5, 3, 5, 10, 15, 20, 30 and 60 min after salbutamol inhalation. The primary ecacy variable was the
maximum percentage change in FEV1 from the post-challenge value. The secondary ecacy variable was area
under the curve (AUC) of FEV1. At the end of the study, acceptability of salbutamol Easyhaler
1 was evaluated
using a questionnaire and Easyhaler1 was also compared with the inhalation device the patient had used earlier.
Twenty-six patients completed the study. Both salbutamol Easyhaler1 and salbutamol Turbuhaler1 produced a
rapid and significant increase in FEV1, with maximum percentage changes being 43?9% (+15?3) and 40?5%
(+21?9) from the post-challenge value, respectively. There were no significant differences between the two
inhalation devices in terms of changes in FEV1 or AUC of FEV1. The use of Easyhaler
1 and getting a new dose
from Easyhaler1 was considered to be very easy by 65% and easy by 35% of the patients. None considered it
dicult. Of 16 patients who had used Turbuhaler1 earlier, 19% considered Easyhaler1 much better, 44% better,
and 38% the same as Turbuhaler1, and none considered it worse.
In conclusion, the results show that salbutamol Easyhaler1 was at least as effective as salbutamol Turbuhaler1
in the treatment of histamine-induced bronchoconstriction. In addition, the patients considered Easyhaler1 very
easy or easy to use. The majority of patients who reported Turbuhaler1 as their own inhaler considered Easyhaler1
better or much better than Turbuhaler1.
Key words: Easyhaler1; Turbuhaler1; salbutamol; asthma; histamine-induced bronchoconstriction; hyper-
reactivity.
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Salbutamol is a potent bronchodilator, acting through
selective b-2 adrenergic receptor agonism. It rapidly relieves
the symptoms of asthma (1) and protects against acute
bronchoconstriction induced by stimuli such as exercise or
inhalation of cold, dry air (2). While the use of pressurizedCorrespondence should be addressed to: Matti Silvasti, Orion
Corporation, Orion Pharma, P.O. Box 1780, FIN-70701 Kuopio,
Finland. Fax þ358-(0)17-245 444; E-mail: matti.silvasti@orion.fi
0954-6111/00/111097+06 $35?00/0metered dose inhalers (pMDIs) for the delivery of
salbutamol has proven useful for many patients, it is
associated with a number of problems. These include the
potential for poor coordination between dose delivery and
inhalation, and the drawbacks of CFC-containing propel-
lants, which are both airway irritants (3) and are about to
be banned due to their damaging effect on the ozone layer
(4,5). Even currently available substitute propellants have
some ‘greenhouse gas’ effects (6). Taking these factors into
consideration dry powder inhalers present a better alter-
native for inhaled asthma therapy. They are# 2000 HARCOURT PUBLISHERS LTD
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and operate without the need for environmentally dama-
ging propellants.
The aim of the present study was to compare the ecacy
of salbutamol delivered by the new-generation, multidose,
dry powder inhaler, Easyhaler1, with that of another
widely used multidose dry powder inhaler, Turbuhaler1, in
histamine-induced bronchoconstriction in asthmatic and/or
hyper-reactive patients.
Materials and methods
PATIENTS
Adult outpatients with documented asthma and/or hyper-
reactivity were considered eligible for the study if their
asthma medication had been constant for at least 4 weeks
prior to the study and their forced expiratory volume in 1
sec (FEV1) was over 65% of predicted values. Patients were
also required to give written informed consent to partici-
pate in the study.
Exclusion criteria included chronic bronchitis or emphy-
sema, respiratory tract infection or vaccination with live-
attenuated influenza viruses within 4 weeks prior to the
study, manifest cardiac failure (NYHA class II–IV), severe
hepatic or renal disease, uncontrolled hyperthyroidism or
insulin-dependent diabetes, pregnancy, inadequate contra-
ception, smoking, alcohol or drug abuse or participation in
another clinical study within 4 weeks prior to this one.
Patients were also excluded if they had taken beta-blockersFIG.1. Study design.within 4 weeks, ephedrine preparations or oral anti-
histamines within 5 days, or acrivastine within 1 day prior
to study drug administration.
STUDY DESIGN
The study was carried out according to a randomized,
double-blind, double-dummy, cross-over design on 2 days
separated by at least 7 days (Fig. 1) in two centres in
Sweden. Before each study day, patients were required to
abstain from controlled-release theophylline preparations
and long-acting sympathomimetics for 48 h, from inhaled
anti-cholinergics and sodium cromoglycate for 12 h, and
from short-acting sympathomimetics for 6 h. Patients were
not allowed to drink coffee, tea, or caffeine-containing soft
drinks for 4 h prior to spirometry measurements. Treat-
ments for concomitant diseases were continued unchanged
during the study.
Histamine challenge tests were performed at the same
time of day (+ 1 h) on both study days. Before each test,
FEV1 and forced vital capacity (FVC) were measured
(Vitalograph Compact Spirometer, Vitalograph Ltd, U.K.)
three times and the best value was chosen. Prechallenge
FEV1 had to be more than 65% of predicted values and, on
the second study day, within 15% of that recorded on the
first study day. After spirometry but prior to the histamine
challenge test, the patients received four breaths of isotonic
saline using a jet nebulizer (Spira Elektro 21, Spira
Respiratory Care Centre Ltd, Ha¨meenlinna, Finland), with
TABLE 1. Demographic and baseline patient information
n 32
Male/female 9/23
Mean age, years (range) 36?6 (19?0–56?0)
Mean height, cm (range) 168?9 (153?0–188?0)
Mean weight, kg (range) 70?6 (52?0–94?0)
No. of atopic patients 21
Asthma severity
(number of patients)*:
Mild 22
Moderate 10
Severe 0
Mean duration of asthma,
years (range){:
Symptoms 19?6 (3?0–53?0)
From diagnosis 12?8 (0–48?0)
Mean prechallenge FEV1,
l (range):
Easyhaler1 3?1 (2?0–5?4)
Turbuhaler1 3?1 (1?9–4?9)
*The severity of asthma was graded according to the
International Consensus Report on Diagnosis and Treat-
ment of Asthma (19).
{n¼30.
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spirometry was then repeated.
The histamine challenge test was then started and
increasing cumulative doses of histamine were inhaled.
Two minutes after each dose, a single FEV1 was measured
and the challenge was continued until FEV1 was decreased
by 20% from the post-saline value. At this point, the
histamine challenge was terminated and a 100 mg dose of
salbutamol was administered either by Easyhaler1 (Bu-
ventol Easyhaler1 100mg dose71; Orion Pharma, Espoo,
Finland) or by Turbuhaler1 (Inspiryl Turbuhaler1 100mg
dose71; AstraZeneca, Lund, Sweden). The correct inhala-
tion technique was demonstrated for each device and the
study drug was inhaled under the supervision of the study
personnel. Spirometry was performed 1?5, 3, 5,10, 15, 20, 30
and 60 min after inhalation of the study drug. If a 20%
decrease in FEV1 was not reached at the maximum
cumulative dose of histamine (2000mg) on the first study
day, the patient was withdrawn from the study.
The primary ecacy variable was the maximum percen-
tage change in FEV1 from the post-challenge value. The
secondary ecacy variable was area under the curve (AUC)
of FEV1. Additional variables were FVC, which was
measured 10, 30 and 60 min after inhalation of the study
drugs, and acceptability of Easyhaler1, which was eval-
uated at the end of the study using a questionnaire with six
questions. The questionnaire was given to the patients to fill
in without help or suggestions. At the end of each study
day, patients were also asked about the occurrence of any
adverse events.
The study was approved by the local Ethics committees
and was conducted in accordance with the Declaration of
Helsinki.
STATISTICAL ANALYSIS
The study was designed to demonstrate that there was no
difference between Easyhaler1 and Turbuhaler1 in terms of
the ecacy of salbutamol inhalation. The sample size
calculation was based on an assumed within-patient varia-
tion of 0?015 l2 for the maximum value of FEV1. The target
power of the study was 0?9 with a 5% significance level. In
order to detect a difference of 0?125 l between the treatments
in maximum value of FEV1 using a two-sided test,
approximately 20 evaluable patients were needed.
The analysis of covariance (ANCOVA) model, including
terms for patient, treatment period and sequence, was used
to analyse ecacy variables. The information provided by
baseline measurements was exploited through the use of
covariates. Estimates of treatment difference with 95%
confidence intervals was calculated. Both intention-to-treat
(ITT) and per protocol (PP) approaches were used in the
ecacy analyses.
Results
PATIENTS
Of the 32 patients enrolled, 26 patients completed the study.
Patient demographic and baseline information is shown inTable 1. Mean prechallenge FEV1 was the same prior to
inhalation via Easyhaler1 or Turbuhaler1. Thirty-eight
percent of the patients were using inhaled corticosteroids,
or sodium cromoglycate before and during the study.
EFFICACY
Twenty-five patients were evaluable for ecacy. Inhalation
of saline had no effect on FEV1. The mean (+SD)
cumulative dose of histamine causing a 20% decrease in
FEV1 was 943mg(+667) before inhalation of salbutamol
from Easyhaler1 and 976 mg (+981) before inhalation
from Turbuhaler1. The mean decrease in FEV1 induced by
these doses was almost identical (Table 2). One patient, in
the Turbuhaler1 group, did not reach a 20% decrease in
FEV1 on the second study day at the highest cumulative
dose of histamine given. In the case of this patient, a value
of 4000 mg was used in the calculation of mean cumulative
dose of histamine, causing a 20% decrease in FEV1.
According to the ITT analysis, there were no statistically
significant differences between Easyhaler1 and Turbuha-
ler1 in terms of any of the ecacy variables (Tables 2 and
3, Fig. 2). The treatment difference in maximum percentage
change for FEV1 was 1?3 percentage units with 95% CI
ranging from 71?2 to 3?7 percentage units. The FVC
values (Table 3) were in accordance with the FEV1 results,
reaching a maximum 30 min after salbutamol inhalation
with both devices.
ACCEPTABILITY
The twenty-six patients who completed the study were
included in the acceptability analysis. Both the use of
TABLE 2. Mean (+SD) changes in FEV1 values (n = 25)
Easyhaler1 Turbuhaler1
Decrease in FEV1 after maximum histamine challenge (l) 0?88 0?79
Increase in FEV1 after salbutamol (%) 43?9 (+15?3) 40?5 (+21?9)
Absolute improvement in FEV1 after salbutamol (l) 0?95 0?84
Mean AUC of FEV1 during 60 min follow-up (l min
71) 46?3(+24?0) 40?2 (+17?8)
FIG. 2. Forced expiratory volume in 1 sec (FEV1) before histamine challenge and after 100 mg dose of salbutamol inhaled
from Easyhaler1 ( . ) and from Turbuhaler1 (o) multi-dose powder inhaler. Means +SD, n=25.
TABLE 3. Mean (+SD) FVC values at baseline and 30 min
after salbutamol (n ¼ 25)
Easyhaler1 Turbuhaler1
Baseline FVC (l) 3?98 (+1?00) 3?97 (+0?99)
Maximum FVC 30 min
after salbutamol (l) 3?96 (+1?09) 3?87 (+1?03)
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considered very easy or easy by all the patients (Table 4).
Inhalation from Easyhaler1 was also considered to be very
easy, or easy by 96% of the patients. Compared to their
previous inhalers, approximately half the patients consid-
ered Easyhaler1 better, or much better. Among 16 patients
who used Turbuhaler1 as their own inhaler, Easyhaler1
was considered to be much better by 19%, better by 44%,
and similar by 38%. Most of the patients felt that
Easyhaler1 was ‘good’ or ‘excellent’ overall, and stated
that they would use Easyhaler1 in the future.SAFETY
All 32 patients were included in the safety analysis. Eight
patients reported AEs with Easyhaler1 and four patients
with Turbuhaler1 after salbutamol inhalation. The number
of events after Easyhaler1 treatment was 15 and five after
Turbuhaler1. Adverse events were mainly rated to be mild
or moderate. Only two events (both headaches) were rated
to be severe. Most reported events were symptoms of
common cold or allergy. One patient had influenza-like
symptoms on the second study day and the study was
discontinued. Only in one case was the event (headache)
assessed to be an adverse drug reaction (Table 5).
Discussion
Both Easyhaler1 and Turbuhaler1 have been shown to
achieve high pulmonary deposition in the administration of
b2-agonists (7). Previous studies have also shown that
delivery of salbutamol from Turbuhaler1 is as effective (8)
or more effective (9,10) than delivery of the same dose of
TABLE 4. Acceptability questionnaire (% of patients; n ¼ 26)
Very easy Easy Neither easy nor dicult Dicult Very dicult
1. Inhalation from Easyhaler1 73?1 23?1 3?8 0 0
2. Getting a new dose from Easyhaler1 65?4 34?6 0 0 0
3. Use of Easyhaler1 65?4 34?6 0 0 0
Much better Better Almost the same Worse Much worse
4. Compared to your previous inhaler* 15?4 38?5 34?6 11?5 0
Excellent Good Neither good nor poor Not so good Not good at all
5. General opinion about Easyhaler1 38?5 50?0 11?5 0 0
Yes, positively Yes Possibly Hardly Absolutely not
6. Use of Easyhaler1 in the future 38?5 50?0 11?5 0 0
*Patient’s own inhaler before the study: Turbuhaler1 61?5% of patients; Aerosol 15?4%; Diskus1 11?5%; Diskhaler1 11?5%.
TABLE 5. Adverse events reported during the study:
symptoms and severity (n¼32)
Treatment Symptom Severity Causality
Easyhaler1 Pharyngitis Mild None
Headache Severe None
Nausea Moderate None
Conjunctivitis Mild Unlikely
Coughing Moderate Unlikely
Rhinitis Mild Unlikely
Headache Mild Possible
Allergy
aggravated Moderate None
Worsening of
asthma Moderate None
Nausea Moderate None
Pharyngitis Mild None
Fever Mild None
Headache Severe None
Conjunctivitis Mild None
Dyspnoea Moderate None
Turbuhaler1 Conjunctivitis Mild Unlikely
Dyspnoea Mild None
Rhinitis Moderate None
Influenza-like
symptoms Moderate None
Rhinitis Mild None
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salbutamol selected for the present study was relatively
low (100mg), and the salbutamol dose–response curve is
steepest at low doses (11), this should make any possible
differences in response between Easyhaler1 and Turbuha-
ler1 easily detectable. In fact, the results of the study
confirmed that salbutamol delivered by Easyhaler1 was at
least as effective as the same dose of salbutamol deliveredby Turbuhaler1 at relieving histamine-induced broncho-
constriction. These data support earlier findings that the
ecacy of a 100mg dose of salbutamol via Easyhaler1 dry
powder inhaler is comparable to that of a 250mg dose of
terbutaline via Turbuhaler1 (12) and 100mg of salbutamol
via pMDI (13).
Easyhaler1 also has the advantage of being non-flow-
dependent (14). This is important since one of the biggest
problems in asthma therapy is incorrect use of inhalers (2).
Thus, for most patients Easyhaler1 appears to fulfil the
definition of an ideal inhalation device: that is, it is easy to
use, portable, contains multiple doses without constant
refilling, requires minimal co-ordination between actuation
and inhalation, and wastes little drug within the device (15).
In the present study, almost all patients considered Easy-
haler1 very easy or easy to use. The majority of the patients
who were familiar with Turbuhaler1 also preferred Easy-
haler1 over Turbuhaler1. These results are in accordance
with the results found earlier (16).
Salbutamol inhaled from both Easyhaler1 and Turbu-
haler1 was generally well-tolerated. Most of the adverse
events reported were mild in nature and were symptoms of
common cold or allergy. Many events were also of the type
that was as likely to have been induced by the histamine
challenge as by salbutamol dry powder inhalation. In fact,
no patients reported skeletal muscle tremor, tachycardia or
palpitations, which have been described previously as the
main adverse events associated with salbutamol inhalation
(17,18).
CONCLUSIONS
In conclusion, the results of this study show that a 100 mg
dose of salbutamol via Easyhaler1 is as at least as effective
as the same dose via Turbuhaler1 after histamine-induced
bronchoconstriction. All patients considered Easyhaler1
easy, or very easy to use, and the majority of patients with
prior experience of Turbuhaler1 described Easyhaler1 as
better, or much better than Turbuhaler1. Salbutamol
1102 O. ZETTERSTRO¨M ET AL.delivery from either device was generally well-tolerated and
safe.
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